Home HOME Neoplasma 2020 Neoplasma Vol.67, No.4, p.715–723, 2020

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.67, No.4, p.715–723, 2020

Title: Adverse events and management of apatinib in patients with advanced or metastatic cancers: A review
Author: F. Shao, H. Zhang, X. Yang, X. Luo, J. Liu

Abstract: Apatinib (YN968D1) is a novel and highly selective tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2) and is approved as a third-line and subsequent-line treatment for advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma in China. Apatinib is also widely studied in other solid tumors. With the increase in clinical research of apatinib, its adverse effects have also received widespread attention. Hence, this article summarizes the pharmacological properties of apatinib and reviews its clinical use in advanced or metastatic cancers. We highlight the common adverse reactions of apatinib in clinical applications and we also clarify the corresponding prevention and intervention measures. Overall, this review will help us better understand the safety and efficacy of apatinib treatment.

Keywords: apatinib, VEGFR, adverse effects, malignant cancer, antiangiogenic targeted therapy
Published online: 07-Apr-2020
Year: 2020, Volume: 67, Issue: 4 Page From: 715, Page To: 723

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.